Valuation: Innate Pharma

Market Cap 112M 124M 104M 93.84M 177M 11.62B 183M 1.25B 495M 6.24B 464M 455M 19.75B P/E 2026 *
3.04x
P/E 2027 * 1.33x
Enterprise Value 57.44M 63.23M 53.07M 47.94M 90.47M 5.94B 93.65M 638M 253M 3.19B 237M 232M 10.09B EV / Sales 2026 *
1.21x
EV / Sales 2027 * -0.48x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day+3.00%
1 week-5.36%
Current month-1.59%
1 month-5.07%
3 months-31.56%
6 months-36.55%
Current year-22.85%
1 week 1.2
Extreme 1.2
1.42
1 month 1.17
Extreme 1.174
1.42
Current year 1.03
Extreme 1.03
2.33
1 year 1.03
Extreme 1.03
2.33
3 years 1.03
Extreme 1.03
2.8
5 years 1.03
Extreme 1.03
4.84
10 years 1.03
Extreme 1.03
15.83
Manager TitleAgeSince
Chief Executive Officer - 01/11/2024
Director of Finance/CFO 51 01/04/2021
Chief Tech/Sci/R&D Officer 57 01/09/2026
Director TitleAgeSince
Chairman 66 01/01/2024
Director/Board Member 65 27/04/2015
Director/Board Member 60 19/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/8/26
BPIFrance Participations SA /PRIVATE EQUITY/
BuyCompany 1,764,705 1.8789%
20/1/26 Buy

Executive/Senior Manager

50,000 0.0542%
16/1/26 Buy

Chief Financial Officer

50,000 0.0542%
Change 5-day change 1-year change 3-year change Capi.($)
+3.00%-5.36%-21.07%-45.67% 124M
-1.29%-1.76%+51.98%+64.66% 66.33B
-0.09%+2.79%+10.75%+95.02% 60.62B
+0.63%+1.64%+24.25%+89.70% 55.5B
-0.81%-0.92%+9.79%+118.58% 47.58B
-0.27%-5.06%+22.49%+29.26% 43.69B
-3.15%-16.63%+141.36%+685.29% 37.27B
+0.23%+1.66%+14.85%+49.06% 36.57B
+2.35%-3.61%+78.64%+60.70% 32.22B
+2.18%+6.38%-37.43%+405.36% 26.58B
Average +0.30%-0.15%+29.56%+155.20% 41B
Weighted average by Cap. -0.18%+0.33%+35.03%+152.54%

Financials

2026 *2027 *
Net sales 47.48M 52.26M 43.87M 39.63M 74.78M 4.91B 77.41M 528M 209M 2.63B 196M 192M 8.34B 89.32M 98.31M 82.52M 74.54M 141M 9.23B 146M 992M 393M 4.95B 369M 361M 15.69B
Net income -859K -946K -794K -717K -1.35M -88.78M -1.4M -9.54M -3.78M -47.64M -3.55M -3.47M -151M 12.52M 13.78M 11.57M 10.45M 19.72M 1.29B 20.42M 139M 55.14M 695M 51.73M 50.63M 2.2B
Net Debt -55M -60.54M -50.82M -45.9M -86.62M -5.68B -89.67M -611M -242M -3.05B -227M -222M -9.66B -155M -171M -143M -129M -244M -16.03B -253M -1.72B -683M -8.6B -641M -627M -27.25B
Projected Income Statement - Annual - Innate Pharma
Logo Innate Pharma
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - government financing for research expenditure (68.9%); - revenues from collaboration and licensing agreements (31%); - other (0.1%). At the end of 2025, the company had a portfolio of 8 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 3 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas, IPH5201 for the treatment of cancer and IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia) and 4 in phase I (IPH4502 and IPH5301 for the treatment of solid tumours, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).
Employees
120
Date Price Change Volume
17/11/26 EUR 1.236 +3.00% 478,469
13/11/26 EUR 1.200 -9.50% 1,072,958
12/11/26 EUR 1.326 -4.33% 543,667
11/11/26 EUR 1.386 +5.00% 641,187
10/11/26 EUR 1.320 +1.07% 153,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Innate Pharma
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.200EUR
Average target price
5.933EUR
Spread / Average Target
+394.44%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Innate Pharma